Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.10.2010 | Brief Report

Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation

verfasst von: A. Lasa, T. Ramón y Cajal, G. Llort, J. Suela, J. C. Cigudosa, M. Cornet, C. Alonso, A. Barnadas, M. Baiget

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Mutations in BRCA1 and BRCA2 genes confer a high risk of breast and ovarian cancer but the incomplete penetrance of these mutations suggests that other genetic and/or environmental factors may modify this risk. We present a family where all affected members carried a mutation in the BRCA1 gene and the index case had suffered from cancer twice in the last 27 years, whereas her monozygotic twin sister, also a carrier of the mutation, remained healthy. As copy number variants (CNVs) contribute to phenotypic diversity, a comparative genomic hybridization array (CGH) was performed to see whether the differences in the CNV profile were a modifier factor of the phenotype in our monozygotic twins. Our results show that differences in the CNVs profile were not the cause of the extremely variable penetrance observed in our MZ twin. The search for an explanation should not therefore be limited to genetic changes at the level of the DNA sequence.
Literatur
1.
Zurück zum Zitat Collaborative Group in Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Collaborative Group in Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
2.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71CrossRefPubMed
3.
Zurück zum Zitat Wooster R, Bignell G, Lancaster J, Swift S, Seal S et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed Wooster R, Bignell G, Lancaster J, Swift S, Seal S et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792CrossRefPubMed
4.
Zurück zum Zitat Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMed Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMed
5.
Zurück zum Zitat Begg CB, Haile RW, Borg A, Malone KE, Concannon P et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299(2):194–201CrossRefPubMed Begg CB, Haile RW, Borg A, Malone KE, Concannon P et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299(2):194–201CrossRefPubMed
6.
Zurück zum Zitat Milne RL, Osorio A, Cajal TR, Vega A, Llort G et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14(9):2861–2869CrossRefPubMed Milne RL, Osorio A, Cajal TR, Vega A, Llort G et al (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14(9):2861–2869CrossRefPubMed
7.
Zurück zum Zitat Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655CrossRefPubMed Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM et al (2006) A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7):646–655CrossRefPubMed
8.
Zurück zum Zitat Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36CrossRefPubMed Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36CrossRefPubMed
9.
Zurück zum Zitat Rahman N, Seal S, Thompson D, Kelly P, Renwick A et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed Rahman N, Seal S, Thompson D, Kelly P, Renwick A et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167CrossRefPubMed
10.
Zurück zum Zitat Renwick A, Thompson D, Seal S, Kelly P, Chagtai T et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873–875CrossRefPubMed Renwick A, Thompson D, Seal S, Kelly P, Chagtai T et al (2006) ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 38(8):873–875CrossRefPubMed
11.
Zurück zum Zitat Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59CrossRefPubMed Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59CrossRefPubMed
12.
Zurück zum Zitat Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7):870–874CrossRefPubMed Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7):870–874CrossRefPubMed
13.
Zurück zum Zitat Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093CrossRefPubMed Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148):1087–1093CrossRefPubMed
14.
Zurück zum Zitat Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R (2006) Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 98(8):535–544CrossRefPubMed Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R (2006) Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst 98(8):535–544CrossRefPubMed
15.
Zurück zum Zitat Mitchell G, Antoniou AC, Warren R, Peock S, Brown J (2006) Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 66(3):1866–1872CrossRefPubMed Mitchell G, Antoniou AC, Warren R, Peock S, Brown J (2006) Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 66(3):1866–1872CrossRefPubMed
16.
Zurück zum Zitat Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A et al (2010) Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 119(1):221–232CrossRefPubMed Milne RL, Osorio A, Ramón y Cajal T, Baiget M, Lasa A et al (2010) Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 119(1):221–232CrossRefPubMed
17.
Zurück zum Zitat Diez O, Brunet J, Sanz J, del Rio E, Alonso MC, Baiget M (1997) Differences in phenotypic expression of a new BRCA1 mutation in identical twins. Lancet 350(9079):713 Diez O, Brunet J, Sanz J, del Rio E, Alonso MC, Baiget M (1997) Differences in phenotypic expression of a new BRCA1 mutation in identical twins. Lancet 350(9079):713
18.
Zurück zum Zitat Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK et al (2004) Detection of large-scale variation in the human genome. Nat Genet 36(9):949–951CrossRefPubMed Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK et al (2004) Detection of large-scale variation in the human genome. Nat Genet 36(9):949–951CrossRefPubMed
19.
Zurück zum Zitat Itsara A, Cooper GM, Baker C, Girirajan S, Li J et al (2009) Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet 84(2):148–161CrossRefPubMed Itsara A, Cooper GM, Baker C, Girirajan S, Li J et al (2009) Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet 84(2):148–161CrossRefPubMed
20.
Zurück zum Zitat Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH et al (2006) Global variation in copy number in the human genome. Nature 444(7118):444–454CrossRefPubMed Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH et al (2006) Global variation in copy number in the human genome. Nature 444(7118):444–454CrossRefPubMed
21.
Zurück zum Zitat Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S et al (2008) Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 82(3):763–771CrossRefPubMed Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S et al (2008) Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 82(3):763–771CrossRefPubMed
22.
Zurück zum Zitat Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMed Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMed
23.
Zurück zum Zitat Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J et al (2000) Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–84CrossRefPubMed Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J et al (2000) Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–84CrossRefPubMed
24.
Zurück zum Zitat Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905CrossRefPubMed Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898–5905CrossRefPubMed
25.
Zurück zum Zitat Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout WM et al (2001) Epigenetic instability in ES cells and cloned mice. Science 293:95–97CrossRefPubMed Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout WM et al (2001) Epigenetic instability in ES cells and cloned mice. Science 293:95–97CrossRefPubMed
26.
Zurück zum Zitat Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F et al (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102(30):10604–10609CrossRefPubMed Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F et al (2005) Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102(30):10604–10609CrossRefPubMed
27.
Zurück zum Zitat Singh SM, Murphy B, O’Reilly R (2002) Monozygotic twins with chromosome 22q11 deletion and discordant phenotypes: updates with an epigenetic hypothesis. J Med Genet 39(11):e71CrossRefPubMed Singh SM, Murphy B, O’Reilly R (2002) Monozygotic twins with chromosome 22q11 deletion and discordant phenotypes: updates with an epigenetic hypothesis. J Med Genet 39(11):e71CrossRefPubMed
Metadaten
Titel
Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation
verfasst von
A. Lasa
T. Ramón y Cajal
G. Llort
J. Suela
J. C. Cigudosa
M. Cornet
C. Alonso
A. Barnadas
M. Baiget
Publikationsdatum
01.10.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0877-0

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.